keyword
MENU ▼
Read by QxMD icon Read
search

formulation vaccine

keyword
https://www.readbyqxmd.com/read/28433944/evaluation-of-vaccinal-effectiveness-of-preparations-containing-membrane-antigens-of-leishmania-l-amazonensis-in-experimental-cutaneous-leishmaniasis-model
#1
João G Ribeiro, Amália S Ferreira, Sharon R A Macedo, Norton R D L P Rossi, Mayara C P da Silva, Rosane N M Guerra, Neuza B de Barros, Roberto Nicolete
American tegumentary leishmaniasis (ATL) is considered a neglected disease, for which an effective vaccine or an efficient diagnosis is not yet available and whose chemotherapeutic arsenal is threatened by the emergence of resistance by etiological agents such as Leishmania amazonensis. ATL is endemic in poor countries and has a high incidence in Brazil. Vaccines developed from native parasite fractions have led to the identification of defined antigenic subunits and the development of vaccine adjuvant technology...
April 20, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28432147/cutting-edge-a-dual-tlr2-and-tlr7-ligand-induces-highly-potent-humoral-and-cell-mediated-immune-responses
#2
Alice Gutjahr, Laura Papagno, Francesco Nicoli, Alain Lamoureux, Fabienne Vernejoul, Thierry Lioux, Emma Gostick, David A Price, Gérard Tiraby, Eric Perouzel, Victor Appay, Bernard Verrier, Stéphane Paul
TLR agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. The aim of this study was to evaluate the immunostimulatory properties of a novel compound incorporating covalently linked moieties designed to stimulate both TLR2 and TLR7. This dual TLR2/TLR7 agonist induced the maturation of dendritic cells and primed substantial populations of cytolytic and highly polyfunctional effector CD8(+) T cells in vitro, and safely potentiated the immunogenic properties of a nanoparticulate Ag in vivo, eliciting humoral responses with a balanced TH1/TH2 profile in mice...
April 21, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28429728/a-formulated-tlr7-8-agonist-is-a-flexible-highly-potent-and-effective-adjuvant-for-pandemic-influenza-vaccines
#3
Neal Van Hoeven, Christopher B Fox, Brian Granger, Tara Evers, Sharvari W Joshi, Ghislain I Nana, Sarah C Evans, Susan Lin, Hong Liang, Li Liang, Rie Nakajima, Philip L Felgner, Richard A Bowen, Nicole Marlenee, Airn Hartwig, Susan L Baldwin, Rhea N Coler, Mark Tomai, James Elvecrog, Steven G Reed, Darrick Carter
Since 1997, highly pathogenic avian influenza viruses of the H5N1 subtype have been transmitted from avian hosts to humans. The severity of H5N1 infection in humans, as well as the sporadic nature of H5N1 outbreaks, both geographically and temporally, make generation of an effective vaccine a global public health priority. An effective H5N1 vaccine must ultimately provide protection against viruses from diverse clades. Toll-like receptor (TLR) agonist adjuvant formulations have a demonstrated ability to broaden H5N1 vaccine responses in pre-clinical models...
April 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28421815/cross-protection-conferred-by-immunization-with-a-romph-based-intranasal-fowl-cholera-vaccine
#4
Thanya Varinrak, Pichayanut Poolperm, Takuo Sawada, Nattawooti Sthitmatee
A previous study demonstrated that a recombinant outer membrane protein H (rOmpH)-based intranasal fowl cholera vaccine elicited efficient homologous protection against Pasteurella multocida strain X-73 (A:1) in chickens. The present study aimed to determine the cross protectivity against heterologous P. multocida strains. The rOmpH was purified via electroelution and formulated with two kinds of adjuvants. The vaccine formulations in a total volume of 100 µl were 100 µg rOmpH with 3 µg of Escherichia coli enterotoxin B (LTB) or 10 µg of CpG ODN2007...
April 19, 2017: Avian Pathology: Journal of the W.V.P.A
https://www.readbyqxmd.com/read/28419351/the-effect-of-diatomaceous-earth-in-live-attenuated-infectious-bronchitis-vaccine-immune-responses-and-protection-against-challenge
#5
Ali Nazmi, Rüdiger Hauck, Lynette B Corbeil, Rodrigo A Gallardo
Live virus vaccines are commonly used in poultry production, particularly in broilers. Massive application and generation of a protective local mucosal and humoral immunity with no adverse effects is the main goal for this strategy. Live virus vaccines can be improved by adding adjuvants to boost mucosal innate and adaptive responses. In a previous study we showed that diatomaceous earth (DE) can be used as adjuvant in inactivated vaccines. The aim of this study was to test DE as adjuvant in an Ark-DPI live infectious bronchitis virus (IBV) vaccine after ocular or spray application...
April 17, 2017: Poultry Science
https://www.readbyqxmd.com/read/28418786/evaluation-in-mice-of-the-immunogenicity-of-a-tetravalent-subunit-vaccine-candidate-against-dengue-virus-using-mucosal-and-parenteral-immunization-routes
#6
Laura Lazo Vázquez, Lázaro Gil González, Ernesto Marcos López, Yusleidi Pérez Fuentes, Lázaro Cervetto de Armas, Enma Brown Richards, Iris Valdés Prado, Edith Suzarte Portal, Karem Cobas Acosta, Melyssa Yaugel Novoa, Yaremis Romero Fernández, Gerardo Guillén Nieto, Lisset Hermida Cruz
Our group has developed a subunit vaccine candidate against Dengue virus (DENV) based on two different viral regions, the domain III of the envelope protein and the capsid protein. The chimeric proteins for each serotype (DIIIC1-4), aggregated with the oligodeoxynucleotide 39 M, form the tetravalent formulation named Tetra DIIIC. Tetra DIIIC induces a protective immune response in mice when it is inoculated by intraperitoneal route. However, if children are the main targets for a DENV vaccine, then a needle-free route of administration should be attractive and advantageous...
April 18, 2017: Viral Immunology
https://www.readbyqxmd.com/read/28417343/adjuvant-therapy-for-melanoma
#7
REVIEW
Aya Agha, Ahmad A Tarhini
Systemic adjuvant therapy for surgically resected cutaneous melanoma that is at high risk for disease recurrence and death targets residual micrometastatic disease which is the source of future local or distant relapse. Interferon-alfa (IFNα) has been the most extensively studied in regimens that varied by dosage, route of administration, formulation, and duration of therapy. Most regimens have demonstrated improvements in relapse-free survival (RFS), while the regimen administered at high dosage (HDI) showed improvements in overall survival (OS) in two out of three RCTs...
May 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28417212/lalf32-51-e7-therapeutic-vaccine-induces-antitumor-immunity-against-human-papillomavirus-type-16-e7-expressing-murine-tumor-metastases-in-the-lungs
#8
Milaid Granadillo, Aileen Batte, Aracelys Blanco, Alain B Alfonso, José Suárez, Nelson Merino, Rosalina Carballo, Bárbara O González, Yayrí C Prieto, Laura Varas, Dayana Soler, Miladys Limonta, Maelys Miyares, Lizet Aldana, Isis Torrens
One important goal of cancer immunotherapy is to prevent and treat tumor metastasis. We have previously reported the significant antitumor effect induced by the immunization with our human papillomavirus therapeutic protein-based vaccine (LALF32-51-E7) without adjuvant and admixed with clinically relevant adjuvants in the subcutaneous TC-1 tumor challenge model. In the present study, we evaluated the efficacy of the above mentioned vaccine formulations in controlling the hematogenous spread of TC-1 tumor cells using a more tumourigenic clone named TC-1* and other intravenous injection site less stressful than the tail vein...
April 17, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28416600/induction-of-an-ifn-mediated-antiviral-response-by-a-self-amplifying-rna-vaccine-implications-for-vaccine-design
#9
Timothy Pepini, Anne-Marie Pulichino, Thomas Carsillo, Alicia L Carlson, Farid Sari-Sarraf, Katrin Ramsauer, Jason C Debasitis, Giulietta Maruggi, Gillis R Otten, Andrew J Geall, Dong Yu, Jeffrey B Ulmer, Carlo Iavarone
RNA-based vaccines have recently emerged as a promising alternative to the use of DNA-based and viral vector vaccines, in part because of the potential to simplify how vaccines are made and facilitate a rapid response to newly emerging infections. SAM vaccines are based on engineered self-amplifying mRNA (SAM) replicons encoding an Ag, and formulated with a synthetic delivery system, and they induce broad-based immune responses in preclinical animal models. In our study, in vivo imaging shows that after the immunization, SAM Ag expression has an initial gradual increase...
April 17, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28413427/immunogenicity-and-safety-of-a-respiratory-syncytial-virus-fusion-protein-rsv-f-nanoparticle-vaccine-in-older-adults
#10
Louis Fries, Vivek Shinde, Jeffrey J Stoddard, D Nigel Thomas, Eloi Kpamegan, Hanxin Lu, Gale Smith, Somia P Hickman, Pedro Piedra, Gregory M Glenn
BACKGROUND: A preventative strategy for Respiratory Syncytial Virus (RSV) infection constitutes an under-recognized unmet medical need among older adults. Four formulations of a novel recombinant RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant) administered concurrently with a licensed inactivated trivalent influenza vaccine (TIV) in older adult subjects were evaluated for safety and immunogenicity in this randomized, observer-blinded study...
2017: Immunity & Ageing: I & A
https://www.readbyqxmd.com/read/28412170/lipid-nanoparticle-systems-for-enabling-gene-therapies
#11
REVIEW
Pieter R Cullis, Michael J Hope
Genetic drugs such as small interfering RNA (siRNA), mRNA, or plasmid DNA provide potential gene therapies to treat most diseases by silencing pathological genes, expressing therapeutic proteins, or through gene-editing applications. In order for genetic drugs to be used clinically, however, sophisticated delivery systems are required. Lipid nanoparticle (LNP) systems are currently the lead non-viral delivery systems for enabling the clinical potential of genetic drugs. Application will be made to the Food and Drug Administration (FDA) in 2017 for approval of an LNP siRNA drug to treat transthyretin-induced amyloidosis, presently an untreatable disease...
April 13, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28410369/quantitative-assessment-of-the-impact-of-partially-protective-anti-schistosomiasis-vaccines
#12
Ramzi A Alsallaq, David Gurarie, Martial Ndeffo Mbah, Alison Galvani, Charles King
BACKGROUND: Mass drug administration (MDA) of praziquantel has been the intervention of choice against schistosomiasis but with limited success in interrupting the transmission. The development of anti-Schistosoma vaccines is underway. Our objective is to quantify the population-level impact of anti-Schistosoma vaccines when administered alone and in combination with mass drug administration (MDA) and determine factors in vaccine design and public health implementation that optimize vaccination role in schistosomiasis control and elimination...
April 14, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28410301/dendritic-cell-strategies-for-eliciting-mutation-derived-tumor-antigen-responses-in-patients
#13
Sreekumar Balan, John Finnigan, Nina Bhardwaj
Dendritic cells (DCs) are equipped for sensing danger signals and capturing, processing, and presenting antigens to naive or effector cells and are critical in inducing humoral and adaptive immunity. Successful vaccinations are those that activate DCs to elicit both cellular and humoral responses, as well as long-lasting memory response against the target of interest. Recently, it has become apparent that tumor cells can provide new sources of antigens through nonsynonymous mutations or frame-shift mutations, leading to potentially hundreds of mutation-derived tumor antigens (MTAs) or neoantigens...
March 2017: Cancer Journal
https://www.readbyqxmd.com/read/28402260/dna-plasmid-vaccine-carrying-chlamydia-trachomatis-ct-major-outer-membrane-and-human-papillomavirus-16l2-proteins-for-anti-ct-infection
#14
Ledan Wang, Yiqi Cai, Yirong Xiong, Wangqi Du, Danwei Cen, Chanqiong Zhang, Yiling Song, Shanli Zhu, Xiangyang Xue, Lifang Zhang
Chlamydia trachomatis (Ct) is one of the most frequently encountered sexual infection all over the world, yielding tremendous reproductive problems (e.g. infertility and ectopic pregnancy) in the women. This work described the design of a plasmid vaccine that protect mice from Ct infection, and reduce productive tract damage by generating effective antibody and cytotoxic T cell immunity. The vaccine, s was composed of MOMP multi-epitope and HPV16L2 genes carried in pcDNA plasmid (i.e. pcDNA3.1/MOMP/HPV16L)...
March 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28400145/vaccination-of-cattle-against-bovine-viral-diarrhea-virus
#15
Benjamin W Newcomer, Manuel F Chamorro, Paul H Walz
Bovine viral diarrhea virus (BVDV) is responsible for significant losses to the cattle industry. Currently, modified-live viral (MLV) and inactivated viral vaccines are available against BVDV, often in combination with other viral and bacterial antigens. Inactivated and MLV vaccines provide cattle producers and veterinarians safe and efficacious options for herd immunization to limit disease associated with BVDV infection. Vaccination of young cattle against BVDV is motivated by prevention of clinical disease and limiting viral spread to susceptible animals...
April 6, 2017: Veterinary Microbiology
https://www.readbyqxmd.com/read/28397465/variation-of-housekeeping-genes-in-clinical-isolates-and-vaccine-strains-of-bordetella-pertussis
#16
Masoumeh Fathi, Faezeh Haghighi, Fereshteh Shahcheraghi, Ebrahim Abbasi, Seyed Saeed Eshraghi, Sedighe Ghourchian, Hojjat Zeraati, Mehdi Yaseri, Masoumeh Douraghi, Fazel Shokri
BACKGROUND: Bordetella pertussis causes serious contagious infections, primarily in childhood. A whole-cell vaccine, diphtheria-tetanus-whole cell pertussis (DTwP), has been used to protect against pertussis in children in Iran, but the pertussis cases have been increasing during recent years. We determined the allelic variation level of housekeeping genes in isolates recovered from pertussis patients and vaccine strains used in national vaccination program. METHODS: Five clinical isolates, 2 vaccine strains and a Tohama I strain were studied through multilocus sequence typing (MLST) of housekeeping genes...
April 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28394915/development-of-a-qualitative-assay-for-screening-of-bordetella-pertussis-isolates-for-pertussis-toxin-production
#17
Irina Gates, Marina DuVall, Hong Ju, M Lucia Tondella, Lucia Pawloski
Bordetella pertussis infection has been increasing in the US, with reported cases reaching over 50,000 in 2012, a number last observed in the 1950s. Concurrently, B. pertussis lacking the pertactin protein, one of the immunogens included in the acellular vaccine formulations, has rapidly emerged since 2010, and has become the predominant circulating phenotype. Monitoring the production of the remaining acellular vaccine immunogens, such as pertussis toxin (Pt), is a critical next step. To date, methods for screening Pt have been either through genomic sequencing means or by conventional ELISAs...
2017: PloS One
https://www.readbyqxmd.com/read/28394704/analysis-of-novel-meningococcal-vaccine-formulations
#18
Susu M Zughaier
The protective effect of meningococcal vaccines targeting disease causing serogroups exemplified by the introduction of MenAfriVac™ in Africa, is well established and documented in large population-based studies. Due to the emergence of other meningococcal disease causing serogroups, novel vaccine formulations are needed. There is a high potential for novel nanotechnology-based meningococcal vaccine formulations that can provide wider vaccine coverage. The proposed meningococcal vaccine formulation contains spherical shaped micro and nanoparticles that are biological mimics of Niesseria meningitidis, therefore present to immune system as invader and elicit robust immune responses...
April 10, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28393307/a-dose-response-study-in-mice-of-a-tetravalent-vaccine-candidate-composed-of-domain-iii-capsid-proteins-from-dengue-viruses
#19
Iris Valdés, Ernesto Marcos, Edith Suzarte, Yusleidi Pérez, Enma Brown, Laura Lazo, Karem Cobas, Melyssa Yaugel, Yadira Rodríguez, Lázaro Gil, Gerardo Guillén, Lisset Hermida
Tetra DIIIC is a subunit vaccine candidate based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. This vaccine preparation contains the DIIIC proteins aggregated with a specific immunostimulatory oligodeoxynucleotide (ODN 39M). Tetra DIIIC has already been shown to be immunogenic and protective in mice and monkeys. In this study, we evaluated the immunogenicity in mice of several formulations of Tetra DIIIC containing different amounts of the recombinant proteins...
April 9, 2017: Archives of Virology
https://www.readbyqxmd.com/read/28389097/efficacy-of-a-novel-protein-based-pneumococcal-vaccine-against-nasopharyngeal-carriage-of-streptococcus-pneumoniae-in-infants-a-phase-2-randomized-controlled-observer-blind-study
#20
Aderonke Odutola, Martin O C Ota, Martin Antonio, Ezra O Ogundare, Yauba Saidu, Ebenezer Foster-Nyarko, Patrick K Owiafe, Fatima Ceesay, Archibald Worwui, Olubukola T Idoko, Olumuyiwa Owolabi, Abdoulie Bojang, Sheikh Jarju, Isatou Drammeh, Beate Kampmann, Brian M Greenwood, Mark Alderson, Magali Traskine, Nathalie Devos, Sonia Schoonbroodt, Kristien Swinnen, Vincent Verlant, Kurt Dobbelaere, Dorota Borys
BACKGROUND: Conserved pneumococcal proteins are potential candidates for inclusion in vaccines against pneumococcal diseases. In the first part of a two-part study, an investigational vaccine (PHiD-CV/dPly/PhtD-30) containing 10 pneumococcal serotype-specific polysaccharide conjugates (10VT) combined with pneumolysin toxoid and pneumococcal histidine triad protein D (30μg each) was well tolerated by Gambian children. Part two, presented here, assessed the efficacy of two PHiD-CV/dPly/PhtD formulations against pneumococcal nasopharyngeal carriage (NPC) prevalence in infants...
April 4, 2017: Vaccine
keyword
keyword
99932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"